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Posttranscriptional regulation of gene expression of mRNAs containing adenine-uridine rich elements (AREs) in their 3 
untranslated regions is mediated by a number of diﬀerent proteins that interact with these elements to either stabilise or destabilise
them. The present review concerns the TPA-inducible sequence 11 (TIS11) protein family, a small family of proteins, that appears
tointeractwithARE-containingmRNAsandpromotetheirdegradation.Thisfamilyofproteinshasbeenextensivelystudiedinthe
past decade. Studies have focussed on determining their biochemical functions, identifying their target mRNAs, and determining
their roles in cell functions and diseases.
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1.Introduction
Mechanisms of posttranscriptional gene regulation by
micro-RNA (miRNA) and short interfering RNA (siRNA)
have been highlighted in recent years as having important
roles in control of a variety of developmental and functional
processes. The present review concerns a small family of
proteins, the 12-O-tetradecanoylphorbol-13-acetate (TPA)
inducible sequence 11 (TIS11) family, which also function
in posttranscriptional gene regulation and whose func-
tions may overlap and interact with miRNA and siRNA
control mechanisms. The TIS11 family consists of four
mammalian members and include TIS11 (ZFP36, TTP,
Nup475, GOS24), TIS11b (Berg36, ERF-1, ZFP36L1, BRF-
1), and TIS11d (ZFP36L2, ERF-2, BRF-2). The fourth family
member described in rodents, Zfp36l3, was expressed in
mouse placenta, but was not detected in human placenta
or other human tissues [1]. TIS11-like proteins have also
been identiﬁed in drosophila and yeast [2–4]. These proteins
contain two tandemly repeated zinc ﬁnger motifs through
which they bind to adenine uridine (AU) rich elements
(AREs) in mRNA and mediate ARE-mediated mRNA decay
[5]. Table 1 lists the three human TIS11 family members,
their chromosomal locations as well as reported mRNA
targets. This family of proteins have been reported to
promote deadenylation, decapping, and ﬁnally degradation
of mRNAs by either exosome (3 -5  degradation) or XRN1
exonuclease (5 -3  degradation) [6].
AREs are found mostly at the 3  end of many mRNAs
encoding cytokines, transcription factors, cell cycle regula-
tors, and apoptosis regulators. It is estimated that up to
8 %o fm R N A sm a yc o n t a i nA R E s[ 7]. AREs are subdivided
into three classes: Class I, Class II, and Class III. Class II
is further subdivided into Class IIA, IIB, IIC, IID, IIE [6].
Class I is characterised by the AUUUA motif and a U-rich
region. Class III is characterised by a U-rich sequence found
in, for example, the mRNA of c-jun. Class IIA contains ﬁve
consecutive AUUUA pentamer sequences; Class IIB contains
four consecutive AUUUA pentamers; Class IIC contains
three consecutive AUUUA pentamers; Class IID contains
two consecutive AUUUA pentamers, and ﬁnally Class IIE
contains one AUUUA motif [6].
2.The TIS11 FamilyinPosttranscriptional
Gene Regulation
One of the ﬁrst indications that the prototype TIS11 protein
functions as an AU binding protein came from work
which showed that TIS11 inhibited TNFα production from2 Journal of Biomedicine and Biotechnology
macrophages by destabilising its messenger RNA (mRNA)
and this appeared to be due to direct binding of TIS11 to
the TNFα ARE [8]. It was later shown that the optimal
and minimally required RNA sequence for TIS11 binding is
UUAUUUAUU[9–12].Theadenineresiduesandthespacing
between them are critical in ensuring a stable association
between the TIS11 peptide and RNA, even though TIS11
was still able to strongly bind to an AUUUUA peptide, and
intermediately to AUUA and AUUUUUA peptides [9, 10].
TIS11 interaction with the RNA sequence is of relatively high
aﬃnity [10]. It should be noted that AREs are found at the 3 
end of each of the TIS11 family mRNAs suggesting that they
mayregulatethemselvesbyanegativefeedbackloop[13,14].
Overexpression of human TIS11 in HEK293 cells caused
signiﬁcant reduction in the levels of an artiﬁcial reporter
mRNA containing part of the TNF-α 3  untranslated region
(3  UTR), and this was dependent on the amount of
TIS11 plasmid transfected [32]. Similar eﬀects were seen
for rat TIS11b or Xenopus TIS11d, although TIS11d was
less eﬃcient in inducing TNF-α reporter mRNA decay than
TIS11 and TIS11b [32]. Two zinc ﬁnger motifs in TIS11 are
necessary and suﬃcient for binding to the AREs, and also
mediate TNF-α mRNA decay [32]. Similarly, other studies
reported that TIS11 and other members of the TIS11 family
can also mediate decay of mRNA for GM-CSF and IL-3
[15, 33]. Critical residues in the human TIS11 family zinc
ﬁnger domains for binding to the TNF-α ARE probe or
GM-CSF ARE probes were Cys124,C y s 147,H i s
128,C y s 162,
and His
166, and mutations of these residues to other amino
acids completely abolished TIS11 binding [39]. In the same
study it was shown that coexpression of wild type TIS11
and a Cys124R nonbinding mutant resulted in stabilisation
of artiﬁcial reporter TNF-α mRNA, even though wild type
TIS11 was able to bind reporter TNF-α mRNA [39]. This
ﬁnding suggested that the presence of a nonbinding mutant
acts as a dominant negative over TIS11 destabilising activity,
possibly by interacting with proteins that regulate TIS11
destabilising function [39].
TIS11-dependent degradation of mRNA requires dead-
enylation [40]. Deadenylation is strongly induced by TIS11
when two nonamers (UUAUUUAUU) are present in a
sequence, whereas deadenylation and mRNA degradation
by TIS11 in probes containing only one nonamer is much
weaker [12]. The ability of TIS11 to promote deadenylation
was dependent on the presence of Mg+2 and it was suggested
that there is involvement of PolyA speciﬁc ribonuclease
(PARN) in the process. It was shown that TIS11 requires
PARN to promote deadenylation of an ARE containing
mRNA probe [40]. Association between TIS11 and PARN
is indirect rather than direct and other proteins may form
the bridge between them. Alternatively, the presence of
TIS11 may displace an ARE stabilising factor that inhibits
deadenylation caused by PARN [40]. Another study using
immunoprecipitation demonstrated that TIS11 does not
associate directly with PARN [41]. It was also shown
that TIS11 co-immunoprecipitates with hDcp1 and hDcp2
(decapping enzymes), hXrn1 (5 -3  exonuclease), hCcr4
(deadenylase), hRrp4 (a component of the exosome), or
hEdc3 (enhances the activity of the decapping enzymes)
throughtheN-terminaldomain,whereasthezincﬁngersand
the C-terminal domain are not involved in these interactions
[41, 42]. Additionally, deletion of the N-terminal domain
of TIS11 partially abrogated induction of mRNA decay by
TIS11. It was therefore proposed that TIS11 is involved
in deadenylation and degradation of mRNA by recruiting
enzymes such as hDcp1, hDcp2 and hCcr4 through the
N-terminal domain [41]. Other transacting elements may
also be involved in TIS11 function recruited through the
C-terminal domain, since deletion of this domain in both
TIS11 and TIS11b resulted in stabilisation of a β-globin
mRNA containing AREs [41]. One such element may be the
exosome, a multicomponent complex with 3 -5  exonuclease
activity, and it was reported that TIS11 requires and recruits
the exosome speciﬁcally in ARE containing mRNA probes,
to mediate degradation of a deadenylated mRNA [43]. It
was also shown that the exosome consists of 14 diﬀerent
components, among which are hRrp4, hRrp40, hRrp41,
hRrp42, hRrp43, hRrp46, hCsl4, and hMtr3 [43]. It seems
likely that TIS11 mediated mRNA degradation involves
multiple enzymes including PARN, decapping enzymes such
as hDcp1, hDcp2, hEdc3, exonucleases including the exo-
some, and Xrn1 (5 -3  exonuclease) as well, to preferentially
degradeAREcontaining mRNAs[42,43].Figure 1showsthe
pathways and major components of ARE mediated mRNA
decay.
Reported mRNA targets of the TIS11 family include
TNF-αinmanycelltypes[14,24,44–47],GM-CSF[15],IL-3
[16],IL-2[21],IL-6[17],IL-10[30],Ccl2andCcl3[24],1,4-
galactosyltransferase [22], vascular endothelial growth factor
(VEGF) [29], cyclooxygenase-2 [18], plasminogen activator
inhibitor type 2 [19], paired-like homeodomain 2 (Pitx2)
[20], E47 [28], polo-like kinase 3 [31], and TIS11 itself [14].
VEGF mRNA was also reported to be a target of TIS11b
[35] although in TIS11b deﬁcient ﬁbroblasts VEGF levels
were shown to be elevated as a consequence of increased
translation rather than an eﬀect on VEGF mRNA [37]. More
recently, TIS11b has been reported to target and degrade
steroid acute regulatory (STAR) protein mRNA [38]. Utili-
sation of siRNA inhibition for TIS11 revealed that it targets
FOS and p21 in the THP-1 cell line and primary human
monocytes [26] and IL-12 and MIP-2 in macrophages [23].
Similarly, TIS11 is involved in the regulation of c-myc and
cyclin-D following treatment of glioblastoma and prostate
cancer cell lines with rapamycin [25]. This suggests that
TIS11 also regulates certain transcription factors and cell
c y c l er e g u l a t o r s .Ag l o b a ls e a r c hf o rn o v e lm R N At a r g e t s
of TIS11 identiﬁed 250 potential targets and characterised
immediate early response gene 3 (Ier3) mRNA as a novel
target [27]. Notably, in this study Ier3 was clearly shown not
to be a target for TIS11b [27] and in a later study polo-
like kinase 3 was shown also to be a target for TIS11 but
not TIS11b or TIS11d [31]. These examples illustrate that
mRNA targets of TIS11 family members may be diﬀerent for
diﬀerent family members. In fact, there is growing awareness
in the ﬁeld that many in vitro assays designed to measure
mRNAinteractionanddecaymayidentify“nonphysiological
targets” and that “physiological targets” of TTP family
members can best be determined by analysis of mRNAJournal of Biomedicine and Biotechnology 3
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Figure 1: Pathways and major components of ARE-mediated mRNA decay by TIS11 proteins. TIS11 protein binds to the ARE sequence in
the 3  UTR and recruits deadenylases either directly (hCcr4) or indirectly (PARN). Deadenylated mRNA can be recruited by the exosome,
a multiprotein structure containing proteins such as Rrp4, Rrp40, Rrp41, and PM-Scl75 that form the 3  to 5  exoribonuclease complex.
Decapping of mRNA can follow deadenylation mediated by decapping enzymes such as Dcp1 and Dcp2 and degradation of mRNA can then
be mediated by the 5  to 3  Xrn1 exonuclease.
degradation kinetics in knockout mice or cells derived from
knockout mice [27]. Another more recent global analysis of
TIS11 targets identiﬁed 137 potential TIS11 mRNA targets
[30]. Interestingly, only a subset of the putative TIS11 targets
contained the UUAUUUAUU sequence. This implies that
either the RNA binding speciﬁcity of TIS11 proteins is not
fully understood or that TIS11 proteins can be indirectly
recruited to mRNA targets via other RNA-binding proteins,
or that many false positives have been indentiﬁed in target
screens. Table 1 summarises the reported mRNA targets for
TIS11 family proteins and reported mechanisms.
A number of recent studies have reported links between
TIS11andmiRNAfunctionsandprocesses.Dicer,anenzyme
required in the processing of miRNAs, was needed for TIS11
mediated degradation of TNFα ARE [48]. Furthermore,
these studies revealed that miRNA16 can pair with eight
bases in the TNFα ARE and this pairing is required for
TIS11 mediated degradation of TNFα ARE [48]. TIS11
and miR16 do not bind directly to each other but interact
through association with Argonaute/eiF2C family members
[48]. Thus, TIS11 mediated mRNA degradation may require
components of the miRNA processing pathway and indeed
miRNA and TIS11 proteins may act codependently in medi-
ating degradation. TIS11 was also identiﬁed as a component
of the RNAi pathway by a genome wide screen in drosophila
melanogaster [49]. TIS11 genes contain many predicted
targets for miRNA suggesting another level of complexity
in the interrelationship between TIS11 family members and
miRNAs [50]. A picture is therefore emerging of potentially
complex interplay of diﬀerent mechanisms of posttranscrip-
tional gene regulation which include the TIS11 family.
3. Identiﬁcation of HumanTIS11
FamilyMembers
Human TIS11 is located on chromosome 19q13.1, and was
isolated and cloned by several groups after stimulation of
cells with serum, TPA, or insulin [51–53]. Human TIS11b
is located on chromosome 14q22-24 and was isolated from
chronic lymphocytic leukemia cells (CLL) after stimulation
with TPA [54, 55], from human cDNA libraries probed with
the rat cMG1 [13] or as a gene that reversed the phenotype
of mutant H1080 cells which were unable to degrade IL-3
mRNA [34]. Finally human TIS11d is located on 2p22.3-
p21 and was isolated from human cDNA libraries probed
with the mouse TIS11d mRNA [56]. The sequence of each4 Journal of Biomedicine and Biotechnology
Table 1: Human TIS11 family members and reported mRNA targets of the TIS11 family.
Gene Alternative names Chromosomal location Reported mRNA targets reference mechanism
TIS11 ZFP36, TTP, Nup475, GOS24 19q13.1 TNF∗ [8]m R N A s t a b i l i t y
GM-CSF [15]m R N A s t a b i l i t y
IL-3 [16]m R N A s t a b i l i t y
IL-6 [17]m R N A s t a b i l i t y
cyclooxygenase [18]m R N A s t a b i l i t y
PAI type 2 [19]m R N A s t a b i l i t y
Pitx2 [20]m R N A s t a b i l i t y
TIS11 [14]m R N A s t a b i l i t y
IL-2 [21]m R N A s t a b i l i t y
1,4galactosyltransferase [22]m R N A s t a b i l i t y
IL-12 [23]?
Ccl2 [24]m R N A s t a b i l i t y
Ccl3 [24]m R N A s t a b i l i t y
c-myc [25]m R N A s t a b i l i t y
cyclin D1 [25]m R N A s t a b i l i t y
Fos [26]m R N A s t a b i l i t y
Ier3 [27]m R N A s t a b i l i t y
Genome analysis 250 mRNAs [27]m R N A s t a b i l i t y
MIP-2 [23]?
p21 [26]m R N A s t a b i l i t y
E47 [28]m R N A s t a b i l i t y
VEGF [29]m R N A s t a b i l i t y
IL-10 [30]m R N A s t a b i l i t y
Genome analysis 137 mRNAs [30]m R N A s t a b i l i t y
polo-likekinase3 [31]m R N A s t a b i l i t y
TIS11b ZFP36L1, Berg36, ERF-1, BRF-1 14q22-24 TNF [32]m R N A s t a b i l i t y
GMCSF [33]m R N A s t a b i l i t y
IL-3 [34]m R N A s t a b i l i t y
VEGF [35]m R N A s t a b i l i t y
c-IAP2 [36]m R N A s t a b i l i t y
VEGF [37]t r a n s l a t i o n
STAR [38]m R N A s t a b i l i t y
TIS11d ZFP36L2, ERF-2, BRF-2 2p22.3-p21 TNF [32]m R N A s t a b i l i t y
GM-CSF [33]m R N A s t a b i l i t y
IL-3 [33]m R N A s t a b i l i t y
∗ Targets in bold conﬁrmed in cells derived from knockout animals are so-called “physiological” targets.
of the three human genes shows little variation between
individuals, and most polymorphisms are detected in the
introns, promoter, and 3  UTR regions [57]. Thirteen poly-
morphisms were detected in the protein-coding regions of
the three TIS11 family genes and six of these would result in
amino acid changes. In TIS11b a polymorphism generating
a dinucleotide substitution was detected that would prevent
splicing of the single intron of TIS11b but to date the
signiﬁcanceofthisisunknown[57].Furtherpolymorphisms
of TIS11 were identiﬁed in a more recent study and one, an
C to T transition in the protein coding domain of TIS11,w a s
signiﬁcantly associated with rheumatoid arthritis in African-
Americans [58].
TIS11, TIS11b, and TIS11d have all been associated with
induction of mRNA decay (see Table 1), and even though
redundancy in their function has been suggested, studies
with knock-out mice and analysis of tissue distribution
suggest that they may have cell speciﬁc regulation and
functions. TIS11 knock-out mice appear normal at birth but
laterdevelopseverecachexia,autoimmunity,patchyalopecia,
arthritis, and conjunctivitis, which can be reversed by
administration of anti-TNF-α antibody [44]. TIS11b knock-
outmicedonotsurvivetobirthbutdieinuterobetweendays
E8 and E13, due either to failure in chorioallontoic fusion
[59], or to defective extraembryonic vasculogenesis [37].
Mice in which a truncated form of TIS11d was generated,
which left the RNA binding domain and the nuclear export
signalintact[60],appearednormalatbirth,butfemaleswere
infertile. Expression of the TIS11 family in mouse tissues has
shown that the TIS11 protein is highly expressed in spleen,Journal of Biomedicine and Biotechnology 5
thymus, lung, large intestine, and liver, weakly expressed in
brain and pancreas but is not expressed at all in the testis and
uterus[61].TIS11bishighlyexpressedinkidneys,liver,lung,
pancreas, and heart, and weakly in skeletal muscle, colon,
thymus, spleen, small intestine, brain, and peripheral blood
leukocytes [62]. TIS11d is highly expressed in lung, liver,
skeletal muscle, kidneys, pancreas, placenta, and less strongly
in heart and brain [63].
4. Structureof TIS11 Family Members
The structures of the ﬁrst zinc ﬁnger motif of TIS11 [64]
and human TIS11d before and after binding to an ARE
p r o b eh a v eb e e nr e p o r t e d[ 65]. The spacing between the
cysteines and histidine in the zinc ﬁngers (CX8CX5CX3H)
and the length of the linker between the zinc ﬁnger motifs
are conserved between TIS11, TIS11b, and TIS11d. Because
of the similarity of the zinc ﬁnger motifs between the three
family members, it is expected that the model of mRNA
binding to TIS11d will apply to all family members. The ﬁrst
zinc ﬁnger motif of TIS11 was found to be very diﬀerent in
comparisonwithothermetalandzincbindingcoredomains,
in terms of diameter and thickness [64]. For human TIS11d
each of the two zinc ﬁngers is folded independently into a
compact domain connected by a linker sequence [65]. The
structure is stabilised by binding of zinc to side chains of
Cys159,C y s 168,C y s 174,H i s
178 for the ﬁrst zinc ﬁnger (ZF1)
motif and Cys197,C y s 206,C y s 212,H i s
216 for the second zinc
ﬁnger (ZF2). Hydrogen bonds and van der Waals forces are
involved in further stabilisation of this structure [65]. The
orientation of the ﬁngers is ﬁxed, because the linker region
has a relatively rigid structure stabilised by hydrogen bonds
at each end and has little ﬂexibility apart from the central
region (residues 186-189) [65]. TNF-α ARE was used as a
probe in this study, with the sequence 5 -UUAUUUAUU-3 .
Zinc ﬁnger 1 (Arg153-Phe
180) interacted with a single UAUU
subsite on the 3  end while zinc ﬁnger 2 (Lys191-Ala
218)
interacted with the same subsite on the 5  end.
5. Regulation of the TIS11 Family at
themRNA Level
TIS11 family mRNAs are induced by TPA in a wide variety
of cells including CLL cells, mouse ﬁbroblasts, human
epithelial cells, and PC phaeochromocytoma cells [53, 54].
Insulin can induce TIS11 in NIH3T3 mouse ﬁbroblasts [66]
but in RIE-1 cells only TIS11b is up regulated by insulin
while the other two family members remain unaﬀected
[67]. Lipopolysaccharide (LPS) induces TIS11 as early as 30
minutes poststimulation in murine macrophage RAW264.7
cells or human macrophages (THP-1) [14, 68, 69]. TIS11
was also induced by LPS in primary human white blood cells
including lymphocytes, monocytes, and neutrophils [70].
TIS11 can be induced by GM-CSF in myeloid cells [71]a n d
by TGF-β in a T-cell line [72] or a combination of TPA and
ionomycin in T lymphocytes [73]. TIS11 can be induced
by anisomycin (a p38 activator) and further induced by a
combination of anisomycin plus IFN-γ or IFN-β as early as
1 hour poststimulation in mouse embryonic ﬁbroblasts [24].
In the same study it was shown that addition of IFN-γ to LPS
treated primary mouse bone marrow macrophages further
increasedinductionofTIS11mRNAincomparisonwithLPS
treated cells [24]. Glucocorticoids have also been reported
to induce TIS11 mRNA and protein in lung epithelial cells
and this induction may well be important for glucocorticoid
mediated control of inﬂammatory gene expression [74, 75].
The second family member, TIS11b, has been shown to be
induced by TPA, bryostatin, and rituximab in CLL cells
[54, 76, 77], calcium ionophore, anti-IgM and anti-CD20 in
Burkitt’s lymphoma cell lines [55, 78], insulin in RIE-1 cells
[67] parathyroid hormone in human primary osteoblasts
[79] or adrenocorticotropic hormone (ACTH) hormone in
adrenocortical cells [80].
An important consideration is that the kinetics of
induction of the mRNA for TIS11 genes appears to be
dependentonthetypeofstimulusandcelltype.Forexample,
TIS11 mRNA is evident at 15 minutes after insulin or serum
stimulationinmouseﬁbroblastsreturningtoalmostbaseline
levels at two hours [66, 81]. In RAW264.7 cells, TIS11 mRNA
induction by LPS is biphasic with the ﬁrst peak at one
hour and the second peak at ﬁve hours poststimulation
[69]. It has been shown that both phases of the biphasic
TIS11 mRNA induction after LPS treatment in RAW264.7
are regulated through the p38 pathway at the mRNA level
[69] and p38 and ERK pathway at the protein level [82].
Similarly TIS11b peaks at two hours poststimulation and is
clearly above basal levels at four hours after stimulation in
insulin treated RIE-1 cells [67] but in ACTH treated human
adrenocortical cells, peak induction of the gene occurs at
three hours poststimulation and is above the basal levels
for up to 24 hours poststimulation [80]. TPA stimulation
of CLL cells induced TIS11b more strongly and earlier than
bryostatin [76] and in the BL60-2 Burkitts lymphoma cell
line, anti-IgM induced TIS11b more strongly than anti-
CD20 stimulation [78]. H7 (a broad speciﬁcity inhibitor for
the PKC and PKA pathways) did not have any eﬀect on
induction of TIS11b mRNA by TPA or bryostatin in CLL
cells [76]. Similarly, induction of TIS11b in RIE-1 cell line by
insulin was unaﬀected by PKC inhibition, but inhibition of
PI3K pathway by wortmannin partially abrogated induction,
whereas the same PI3K inhibitor had no eﬀect on induction
of TIS11b by TPA [67].
6. Regulation of the TIS11 Family at
the ProteinLevel
TheTIS11familyisalsoregulatedattheproteinlevelthrough
either phosphorylation and/or localisation in diﬀerent cellu-
lar compartments.
6.1. Phosphorylation. The TIS11 protein was suggested to be
phosphorylated since it was noticed that stimulation of the
NIH3T3 cell line with various stimuli such as serum, TPA,
platelet-derived growth factor (PDGF), ﬁbroblast growth
factor (FGF) for 2 hours, induced TIS11 protein detected as
45kDa protein and not as the predicted 33kDa protein [83].
Inthisparticularstudy,phosphorylationofTIS11wasshown
tobe partially regulatedbythe p42 mitogen activatedprotein6 Journal of Biomedicine and Biotechnology
kinase (MAPK) pathway, which phosphorylates Ser220 in
mouse TIS11 [83]. In another study in LPS stimulated
murine macrophages, TIS11 protein was evident at 75
minutes poststimulation as a 36kDa protein, and increased
insizeovertimeupto45kDaat240minutespoststimulation
[84]. TIS11 protein is a substrate for MAPK p38α and p38β
isoforms which probably control multiple phosphorylation
events [84]. TIS11 phosphorylation was also reported to
be mediated by the p38-regulated MAPK activated protein
kinase 2 (MK2) [68]. Ser52,S e r 178,T h r
249,T h r
250,S e r 264,
Ser80/82 were suggested to be the sites of phosphorylation by
MK2 in murine TIS11 and Ser264 and Thr
250 were suggested
to be regulated by the p38a pathway [85]. Addition of a
p38 inhibitor to RAW 264.7 cells previously stimulated by
LPS for 2 hours resulted in rapid TIS11 dephosphorylation
and degradation [82]. TIS11 phosphorylation is therefore in
equilibrium with dephosphorylation probably mediated by
protein phosphatase 2A [86]. Major phosphorylation sites
responsible for murine TIS11 stabilisation were found to be
Ser52 andSer178 whichwerephosphorylatedbyMK2[82,87].
The importance of Ser52 phosphorylation for the cyto-
plasmic localisation of murine TIS11 was demonstrated in
a study which also suggested that Ser178 is important for
this localisation [82]. Interestingly, Ser178 is also present in
murine TIS11b and phosphorylation of this site creates a
binding site for the 14-3-3 β isoform [85]. This is not the
only isoform of 14-3-3 that the TIS11 family can bind to
and it has been shown by a yeast two hybrid system that
all TIS11 family members bind equally well to 14-3-3 η
and β isoforms [88]. A study using MudPIT or MALDI/MS
methods showed that the major phosphorylation sites in
h u m a nT I S 1 1w h e np u r i ﬁ e df r o mH E K 2 9 3c e l l sw e r eS e r 66,
Ser88,T h r
92,S e r 169,S e r 186,S e r 197,S e r 218,S e r 228,S e r 276,
Ser296 [89]. Ser197,S e r 218,a n dS e r 228 were predicted to be
potentialsitesforproteinkinaseA,glycogensynthasekinase-
3, and extracellular-signal-regulated kinase 1 (both Ser218
and Ser228), respectively [89].
Phosphorylation of TIS11 may alter its function as a
destabilizing AU binding protein. One study showed that
transfection of cells with TIS11 and MKK6, which activates
p38, resulted in phosphorylation of TIS11 protein but this
did not aﬀect TIS11 ability to induce mRNA decay [69].
Another study using a series of serine or threonine mutants,
alone or in combination, showed that these phosphorylation
events did not alter the function of TIS11 in terms of TNF-α
induceddestabilisationormRNAbindinganddeadenylation
[47]. A further study showed that cotransfection of HEK293
cells with TIS11 and MKK6(E) dominant active MKK6
resulted in a slight increase in the half life of a TNF-α
construct in comparison with cells transfected with TIS11
alone, suggesting some deactivation or inhibition of TIS11
function following phosphorylation [84]. Furthermore, it
was reported that phosphorylation of murine TIS11 espe-
cially at Ser178 inhibited its binding ability to TNF-α ARE
and thus that the unphosphorylated TIS11 is active in
mRNA degradation [87]. It was proposed that reduced
binding activity of phosphorylated murine TIS11 could be
due to competitive binding with 14-3-3 proteins because
phosphorylation of Ser52 and Ser178 has been reported to
induce binding to 14-3-3 proteins [87]. More recently, it
was reported that phosphorylation of human TIS11b did
not aﬀect its ability to bind to AREs and recruit RNA
degradationenzymesbutdidnonethelessinhibititsabilityto
degrade ARE-containing mRNA [90]. Finally, another study
involving human TIS11b, showed that phosphorylation of
TIS11b by protein kinase B at Ser92 abrogated mRNA decay
of an IL-3 ARE containing probe induced by overexpression
of TIS11b [91].
6.2. Subcellular Localisation of TIS11 Family Members. In
many cell types, TIS11 is expressed at very low/undetectable
levels in the nucleus and cytoplasm of unstimulated cells and
is almost entirely expressed in the cytoplasm of stimulated
cells [82]. However, there was one early report showing
that TIS11 is nuclear and remains nuclear after stimulation
with serum [51]. Another exception appears to be human
umbilical vein endothelial cells (HUVEC) in which TIS11
is cytoplasmic in resting HUVEC and becomes nuclear
after stimulation with TNF-α [22]. Nuclear to cytoplasmic
shuttling of murine Tis11 has been shown to be regulated
through induction of phosphorylation at Ser52 and Ser178,
primarily by the p38 pathway [82]. Hypophosphorylated
forms of TIS11 were found to be nuclear and highly
susceptible to proteasomal degradation [82].
Murine TIS11 has a nuclear export signal (NES) between
amino acids 1–15 [92]. For murine TIS11b B the NES has
been mapped between amino acids 305–313 and for murine
TIS11d between amino acids 471–479 [92]. In a separate
study, the rat TIS11 nuclear localisation signal (NLS) was
mapped to the region containing the tandem repeats of the
zinc ﬁnger motif (amino acids 88–161), and Arg127 and
Arg131,whicharelocatedinthelinkerregionbetweenthetwo
zinc ﬁnger motifs, were shown to be critical residues whereas
Leu3,I s o l16 and Leu10 were critical for nuclear export [93].
It has been shown by a yeast two hybrid system that TIS11
speciﬁcally associates with nucleoporin/Nup214 which is
part of the nuclear pore on the cytoplasmic face of the
pore complex [94] and this protein probably associates with
the linker region between the zinc ﬁnger motifs to mediate
nuclear localisation of TIS11. On the other hand nuclear
export seems to be regulated through CRM1 since inhibition
of CRM1 resulted in nuclear accumulation of TIS11 [93].
When cells are stimulated with a strong stress signal such
asheatshock,TIS11co-localiseswithTIA-1instressgranules
[95]. Localisation of TIS11 in stress granules also occurs
when cells are treated with FCCP (p-triﬂuoromethoxy car-
bonyl cyanide phenyl hydrazone, a mitochondrial inhibitor),
and oxidative stress but MK2 phosphorylation of TIS11
promotes its complex formation with 14-3-3 protein and
excludes it from stress granules [96, 97]. Both zinc ﬁngers
of rat TIS11 are absolutely necessary for localisation in stress
granules,especiallyaminoacidsTyr
105,T yr
113,Phe
119,Gly
109,
and Gly
114 [95]. On the contrary it was shown that arsenite
treatment excludes TIS11 from stress granules through
MK2 mediated or p38 and c-jun N-terminal kinase (JNK)
mediated phosphorylation [47, 96]. TIS11 and TIS11b also
localise to processing bodies (P-bodies), which are cytoplas-
mic foci of mRNAs and enzymes that have been proposed asJournal of Biomedicine and Biotechnology 7
sites of mRNA decay and translational silencing [42, 97, 98].
TIS11 and TIS11b appear to deliver ARE containing mRNAs
to processing bodies for translational silencing and mRNA
decay [98]. Overexpression of TIS11 and TIS11b resulted
in stable association between stress granules and processing
bodies suggesting that the TIS11 family plays an active role
in tethering stress granules to processing bodies [97]. Stress
granules are considered sites where mRNA is sorted for
storage, reinitiation of translation or degradation [97, 99].
Interestingly, formation of processing bodies is absolutely
necessary for RNA interference activity and translation
arrest or mRNA degradation through siRNA and miRNA
[100]. Thus, TIS11 family and miRNA posttranscriptional
functions take place in the same subcellular location as
well as possibly being interdependent and sharing mRNA
degradation machinery [48].
7.TIS11FamilyinCellFunctionsandDisease
Overexpression of TIS11 family members induces apoptosis
in a variety of cell lines including HeLa, U20S, SAOS2,
and 3T3 [101, 102] and B-cell lymphoma cells [77] cells.
Induction of apoptosis by all three TIS11 family members
was completely abrogated in the presence of Bcl-2 or CrmA
[101]. TIS11 synergistically induced apoptosis with TNF-
α in 3T3 cells and the zinc ﬁngers and the N-terminal
domain of TIS11 are absolutely critical for this eﬀect [102].
Mutant TIS11 lacking the zinc ﬁnger motifs failed to induce
apoptosis and localised in the nucleus, whereas the wild type
TIS11 localised in the cytoplasm [102]. The TIS11 family
may regulate degradation of cell survival proteins such as,
Bcl-2, directly. Bcl-2 mRNA contains a Class II ARE motif in
the 3 UTR with at least one UUAUUUAUU nonamer which
is conserved between diﬀerent species and this sequence
controls the stability of Bcl-2 [103]. RNA electrophoretic
shift assays have conﬁrmed an interaction between TIS11b
and the Bcl-2 ARE (Murphy et al., unpublished observa-
tions). Because TIS11 also destabilises several mRNAs whose
overexpression is related to malignant change, it has been
suggested that they may form a class of tumour suppressor
genes. In support of this hypothesis, it has been reported that
injection of mast cells transformed with v-H-Ras resulted in
tumour formation in mice as early as 6 weeks after injection
due to production of autocrine IL-3 [104]. Transfection
with v-H-Ras clones overexpressing TIS11 delayed tumour
f o rmatio nb yatleast4w eeks[104].Another studycorrelated
response to cisplatin in head and neck squamous cell car-
cinoma cell lines with levels of TIS11b expression. Tumour
cells expressing TIS11b underwent apoptosis following drug
exposure, while tumour cells with low/absent levels of
TIS11b were resistant to apoptosis, but became sensitive
after transfection of cells with a TIS11b expressing plasmid
[36]. Interestingly, signiﬁcant downregulation of inhibitor of
apoptosis protein 2 (cIAP2) but not Bcl-2 mRNA was seen
in these cells even though both these mRNAs contain class II
AREs [36].
TIS11 (but not TIS11b) speciﬁcally interacts with the
Tax protein from either bovine leukaemia virus or human
T lymphotropic virus 1 (HTLV-1) through the C-terminal
domain [46]. In the presence of TIS11, Tax was less
oncogenic probably due to inhibition of Tax transactivation
activity [46]. Interestingly TIS11 was able to abrogate TNF-
α induction by Tax in unstimulated RAW264.7 cells [46].
TIS11bexpressionisupregulatedinhumanHTLV-1-infected
cellsbyTaxtransactivatorproteinwhichbindstotwoTIS11b
upstream control elements [105].
TIS11b was found to be one of the genes that are over
expressed in cell lines and primary cells expressing the
AML1-ETO fusion protein, that is, found in 40% of Acute
Myeloid Leukaemia subtype M2 [62]. When ectopically
expressed TIS11b promoted myeloid progenitor L-G cell
proliferation and inhibited diﬀerentiation [62]. Intriguingly,
siRNA mediated TIS11b knockdown in murine embryonic
stem cells promoted their diﬀerentiation to cardiomyocytes
[106]. Increased expression of TIS11b was reported in
primarybreasttumours[107]andhepatocellularcarcinomas
[108]. In addition, TIS11, TIS11b, and TIS11d have been
reportedtobeover-expressedinavarietyoftheNCI60panel
of human cancer cell lines [109].
The involvement of the TIS11 family in inﬂammatory
disease was one of the earliest reported disease associations
of this family. TIS11 knockout mice developed a generalised
autoimmune-like disease that was largely controlled by the
addition of neutralising anti-TNF antibodies [44]. TIS11,
in particular, has been reported to mediate degradation of
inﬂammatory cytokine mRNAs (see Table 1 and references
therein). Recently, targeting TIS11 has been shown to have
therapeutic potential in an animal model of inﬂammatory
bone loss [110].
8. Conclusion
The TIS11 family of proteins mediate posttranscriptional
gene regulation, which appears to be important in a range
of physiological and pathological processes. A number of
important gaps in our knowledge still exist and require
furtherstudy.WehavelimitedknowledgeofmRNAtargetsof
TIS11 family members and whether individual TIS11 family
members target distinct, overlapping, or identical targets
to other family members. A few studies have suggested
inhibition of translation may also be mediated by the TIS11
familyaswellasmRNAdegradationandthisrequiresfurther
elucidation. A most interesting line of enquiry concerns the
relationship of TIS11 family mediated posttranscriptional
regulation to miRNA and siRNA mediated posttranscrip-
tional regulation. Finally, their role in cell functions and
disease have already provided evidence that they may be
useful therapeutic targets in inﬂammatory diseases and
cancer. Further studies are likely to identify other important
regulatory mechanisms for this family in health and disease.
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